Related Experiment Video
Updated: Jul 5, 2026

Synthesis of Cationized Magnetoferritin for Ultra-fast Magnetization of Cells
Published on: December 13, 2016
Protein-binding Properties of two Antitumour Ru(III) Complexes to Human Apotransferrin and Apolactoferrin
F Kratz1, B K Keppler, L Messori
1Department of Inorganic Chemistry University of Heidelberg Im Neuenheimer Feld 270 Heidelberg W - 6900 Germany.
Abstract:
The interaction of two ruthenium(III) complexes exhibiting high anticancer activity - namely trans-Indazolium(bisindazole) tetrachlororuthenate(III), Hlnd[RuInd(2)Cl(4)], and trans-Imidazolium (bisimidazole) tetrachlororuthenate(III), Hlm[RuIm(2)Cl(4)], - with human serum apotransferrin has been investigated through spectroscopic and chromatographic techniques with the ultimate goal of preparing adducts with good selectivity for cancer cells due to the fact that tumour cells express high amounts of transferrin receptors on their cell surface. Whereas the binding of Hlm[RuIm(2)Cl(4)] to human serum apotransferrin takes several hours, Hlnd[RuInd(2)Cl(4)], the less toxic complex, gives rise to a well defined 2:1 complex within a few minutes. Hlnd[RuInd(2)Cl(4)] will react with apotransferrin only in the presence of bicarbonate, this anion dictating the kinetic and mechanistic characteristics of protein-binding. Circular dichroism studies had previously indicated that binding of both Ru(III) complexes occurs around the unoccupied iron(III) binding sites; this result is now confirmed by preliminary X-ray data of Hlnd[RuInd(2)Cl(4)] and Hlm[RuIm(2)Cl(4)] bound to apolactoferrin, a related iron protein. The crystallograhic data reveals that binding of both complexes takes place at histidine residues, and that the ligand (indazole) remains bound in the case of Hlnd[RuInd(2)Cl(4)].
Related Concept Videos
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Drug Distribution: Plasma Protein Binding
The Early Endosome: Endocytosis of Transferrin
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Drug Distribution: Tissue Binding
For...
